Protexi / Celloram - LARVOL DELTA

The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice (Nature) - "In preclinical mouse models of melanoma and breast cancer, PROTEXI significantly reduces tumor growth and improves survival by promoting robust T cell infiltration into immune-cold tumors, increasing cytotoxic T cell responses via epitope spreading, and activating genes linked to optimal DC, NK cell, and T cell function. Furthermore, PROTEXI elicits superior responses when combined with other immunotherapy agents in models of therapy-resistant tumors. Finally, in a humanized mouse model of melanoma, PROTEXI vaccine co-presenting CD4⁺ T-specific Spike epitopes with CD8⁺ T cell-restricted PRAME and MAGE-A3 antigens, significantly reduces tumor burden. Thus, these data underscore the potential of harnessing pre-existing viral-specific immunity to enhance the efficacy of DC vaccines in immune-cold tumors."

Preclinical • Sarcoma • Solid Tumor

The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice. (PubMed, Nat Commun) - "Finally, in a humanized mouse model of melanoma, PROTEXI vaccine co-presenting CD4⁺ T-specific Spike epitopes with CD8⁺ T cell-restricted PRAME and MAGE-A3 antigens, significantly reduces tumor burden. Thus, these data underscore the potential of harnessing pre-existing viral-specific immunity to enhance the efficacy of DC vaccines in immune-cold tumors."

Journal • Preclinical • Breast Cancer • Infectious Disease • Melanoma • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor • CD4 • CD8 • PRAME

Engineering durable tumor immunity with a virus-tumor hybrid antigen dendritic cell vaccine (AACR 2026) - "Combination therapy with either anti-PD-1 immune checkpoint blockade or the ALK5 (TGF-β type I receptor) inhibitor Vactosertib further augmented therapeutic efficacy in therapy-resistant tumor models. Collectively, these findings highlight the clinical potential of PROTEXI as an innovative DC vaccine platform that leverages the widespread prevalence of Spike-specific CD4⁺ T-cell immunity to enhance cancer vaccine efficacy—offering a promising therapeutic strategy for patients with advanced, immune-cold tumors."

IO biomarker • Oncology • CD4 • CD8 • CD80 • IL12A • PRAME • TGFB1 • TGFBR1